Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-6798-5p inhibitor
- Development stage
- Preclinical
- Lead developer
- Maimónides Institute of Biomedical Research of Córdoba
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-6798-5p inhibitor is an antisense oligonucleotide designed to inhibit the activity of microRNA-6798-5p (miR-6798-5p). Developed preclinically by the University of Córdoba and the Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), it is being investigated as a potential therapeutic strategy for prostate cancer, particularly in patients with obesity. miR-6798-5p acts as an oncomiR secreted by periprostatic adipose tissue (PPAT), promoting tumor aggressiveness, proliferation, and migration by repressing the tumor suppressor transgelin-2 (TAGLN2). Inhibition of miR-6798-5p restores TAGLN2 expression, reactivates ribosome biogenesis and rRNA processing pathways, and has been shown to reduce tumor growth in preclinical in vivo models.
- Other names
- hsa-miR-6798-5p inhibitorhsa-miR6798-5p inhibitorhsa-miR 6798-5p inhibitormiR-6798-5p antagomirmiR6798-5p antagomirmiR 6798-5p antagomir
Beyond the preview
Go deeper on miR-6798-5p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-6798-5p inhibitor.